PhonlamaiPhoto/iStock via Getty Images
Beam Therapeutics (NASDAQ:BEAM) shared promising results from the early stage trial of its genetically modified cell therapy, BEAM-101, for the treatment of severe sickle cell disease.
The data revealed that every patient who received BEAM-101 achieved significant improvements. It saw Hemoglobin